Yet another NASH defeat for Gilead as 3-drug cocktail fizzles. Now one analyst says it's time for a change-up
There are an estimated 50 companies focused on developing drugs for NASH, a common liver disease that has long flummoxed researchers, triggering a laundry list of setbacks for the field. Gilead is one of the high-profile casualties.
After two stinging defeats in key late-stage NASH studies (STELLAR-4, STELLAR-3) testing its drug selonsertib — Gilead was banking on a combination approach to take a bite out of the lucrative market that is so far untapped. But that effort has also fizzled, the US drugmaker conceded on Monday.
The trial, dubbed ATLAS, tested evaluated the safety and efficacy of monotherapy and dual combination regimens of three experimental drugs, cilofexor (FXR agonist), firsocostat (ACC inhibitor) and selonsertib (ASK1 inhibitor) in 392 patients with advanced fibrosis caused by NASH. The selonsertib monotherapy arm was dropped out of the trial following the STELLAR failures.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.